The Museum Tinguely, which was founded in 1996 and is dedicated to the work of the Swiss metal sculptor Jean Tinguely, is a cultural commitment by Roche.
In addition to its permanent exhibition of the machine sculptures and graphic works of Jean Tinguely, who died in 1991, the museum also hosts special exhibitions that give an insight into the art and artists who influenced and were associated with Tinguely, kinetic art and 20th and 21st-century art. Current and past exhibitions have been dedicated to such friends and partners of Tinguely as Niki de Saint Phalle, Yves Klein or Eva Aeppli; to role models such as Marcel Duchamp, Kurt Schwitters or Max Ernst; and to more recent trends such as contemporary kinetic art. Exhibitions always focus on new areas of art. Further information on the Museum Tinguely can be found on its website www.tinguely.ch.
bird's eye jazz club
The bird's eye jazz club in Basel has made an excellent name for itself in jazz music circles around the world. Among the smaller clubs, it is one of the most sought-after and renowned venues in Europe. The quality of the groups that perform at the bird's eye is correspondingly high. International formations and the best national and regional as well as newcomer formations provide a lot of variety for the audience and for the international exchange among the musicians. The pleasant ambience of the cozy club venue in the city center and the closeness between audience and musicians are appreciated by both sides. In addition to the main offer, which stylistically lies in the area of modern classical contemporary jazz, musically innovative projects and the networking with other organizers promote these encounters also beyond stylistic boundaries, be it with classical music, hip hop or Latin. It is hard to imagine the Basel region without The bird's eye. More information about the bird's eye can be found on the homepage www.birdseye.ch, (bird's eye jazz club facebook).
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law.